Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06805942 · ClinicalTrials.gov registry record · NA
Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis
A NA study of Plantar Fasciitis of Both Feet, sponsored by IR Centers.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06805942 is a NA study of Plantar Fasciitis of Both Feet that is actively recruiting participants, run by IR Centers. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06805942, a NA study of Plantar Fasciitis of Both Feet, is actively recruiting participants, sponsored by IR Centers.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates the feasibility and safety of using Lipiodol (ethiodized oil) as an investigational embolic agent for treating pain caused by plantar fasciitis. Participants will undergo a minimally invasive procedure called plantar fascia embolization (PFE) to reduce inflammation and pain in the affected area. The study aims to assess changes in pain levels, foot function, and any potential side effects over a six-month follow-up period.
Conditions Studied
Interventions
- DEVICE Lipiodol (ethiodized oil) injection
Study Locations (1)
Virginia
- IR Centers - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06805942
The ClinicalTrials.gov registry entry for NCT06805942 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is IR Centers, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plantar Fasciitis of Both Feet appearing as the primary indexed condition, and to 1 intervention - of which Lipiodol (ethiodized oil) injection is the first listed.
NCT06805942 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06805942 about?
NCT06805942 is a clinical study titled "Embolization for the Treatment of Heel Pain Secondary to Plantar Fasciitis". This study evaluates the feasibility and safety of using Lipiodol (ethiodized oil) as an investigational embolic agent for treating pain caused by plantar fasciitis. Participants will undergo a minimally invasive procedure called plantar fascia embolization (PFE) to reduce inflammation and pain in t...
What is the current status of trial NCT06805942?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-02-15. Estimated completion is 2025-09-30.
What conditions does trial NCT06805942 study?
This clinical trial studies the following conditions: Plantar Fasciitis of Both Feet.
What interventions are being tested in trial NCT06805942?
The interventions under investigation include: Lipiodol (ethiodized oil) injection (DEVICE).
Who is sponsoring clinical trial NCT06805942?
This trial is sponsored by IR Centers, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06805942 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plantar Fasciitis of Both Feet
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.